Continuing Education Activity

The respiratory system provides oxygen to and removes carbon dioxide from the body; however, the inability to perform either or both of these tasks results in respiratory failure. Type 1 respiratory failure occurs when the respiratory system cannot adequately provide oxygen to the body, leading to hypoxemia, and can be caused by alveolar hypoventilation, low atmospheric pressure/fraction of inspired oxygen, diffusion defect, ventilation/perfusion mismatch, and right-to-left shunt. Type 2 respiratory failure occurs when the respiratory system cannot adequately remove carbon dioxide from the body, leading to hypercapnia, and can be caused by respiratory pump failure and increased carbon dioxide production. This activity reviews the evaluation and management of respiratory failure and highlights the role of the healthcare team in evaluating and treating patients with this condition.

Objectives:

• Review the etiology of respiratory failure.
• Explain the pathophysiology of respiratory failure.
• Review the physical exam findings associated with respiratory failure.
• Summarize the treatment considerations for patients with respiratory failure.

Introduction

The respiratory system allows gas exchange between the environment and the body, facilitating the process of aerobic metabolism. Specifically, the respiratory system provides oxygen and removes carbon dioxide from the body. The inability of the respiratory system to perform either or both of these tasks results in respiratory failure. Type 1 respiratory failure occurs when the respiratory system cannot adequately provide oxygen to the body, leading to hypoxemia. Type 2 respiratory failure occurs when the respiratory system cannot sufficiently remove carbon dioxide from the body, leading to hypercapnia. Respiratory failure can be classified based on chronicity (i.e., acute, chronic, and acute on chronic). A thorough understanding of respiratory failure is crucial to managing this disorder. If either type of respiratory failure is not identified and addressed early, it will become life-threatening and lead to respiratory arrest, coma, and death. The approach to adult patients with suspected respiratory failure (both hypercapnia and hypoxic), as well as the diagnosis and treatment of acute and chronic respiratory failure, are discussed in this article. 

Etiology

Respiratory failure can occur if there is an abnormality with any component of the respiratory system. Components of the respiratory system include the upper and lower respiratory tracts, the central and peripheral nervous systems, in addition to the chest wall and muscles of respiration.[1] The pathophysiology section of this article will review specific etiologies of respiratory failure.

Epidemiology

Respiratory failure (RF) is a syndrome caused by a multitude of pathological states; therefore, the epidemiology of this disease process is difficult to ascertain. In 2017, in the United States of America, however, the incidence of respiratory failure was found to be 1,275 cases per 100,000 adults. The case definition used in this study included all diagnosis codes that included respiratory failure as a component.[2] The epidemiology of respiratory failure is dependent mainly on the cause leading to the failure. Below, we list some common causes of respiratory failure and the relevant trends: 

• Acute myocardial infarction-related (AMI-RF): Between the years 2000 and 2014, 439,436 admissions due to AMI-RF were noted in 57% and required mechanical ventilation in 43% of total cases.[3]
• Acute respiratory failure due to acute respiratory distress syndrome (ARDS) ranges in incidence from 10-80/100,000/y based on where it is recorded worldwide. This is partly due to different practices and thresholds for intubation in these cases and the use of different definitions of ARDs. According to one report, it is estimated that 10% of all patients admitted to ICU and 23% of mechanically ventilated patients meet ARDS criteria.[4]
• Acute respiratory failure related to Coronavirus (COVID-19): It is estimated early in the COVID-19 pandemic that up to 79% of hospitalized patients developed respiratory failure requiring invasive mechanical ventilation.[5] 
• Acute exacerbation of COPD (AECOPD) is the third most common etiology in patients hospitalized because of acute respiratory failure.[6]

Pathophysiology

T ype 1 respiratory failure:

The distinguishing characteristic of Type 1 respiratory failure is a partial pressure of oxygen (PaO2) < 60 mmHg with a normal or decreased partial pressure of carbon dioxide (PaCO2). Depending on the cause of hypoxemia, the alveolar-arterial (A-a) gradient may be normal or increased. Formulas of the A-a gradient and alveolar gas equation are provided below, as these concepts are helpful in understanding the pathophysiology of respiratory failure.

     A-a gradient:

• A-a gradient = PAO2 - PaO2, where

  • PAO2 = Alveolar partial pressure of oxygen
  • PaO2 = Arterial partial pressure of oxygen

     Alveolar gas equation:[7]

• PAO2 = FiO2 (PB - Pwater) - PaCO2/0.8, or PIo2= (PB - 47) × FIo2,

  • PAO2 = Alveolar partial pressure of oxygen
  • FiO2 = Fraction of inspired oxygen
  • PB = Barometric (Atmospheric) pressure
  • Pwater = Vapor pressure of water at body temperature (37°C)=47 mmHg
  • PaCO2 = Partial pressure of arterial carbon dioxide

 Etiologies of Type 1 respiratory failure with normal A-a gradients include:

• Alveolar hypoventilation: Alveolar hypoventilation increases the arterial partial pressure of carbon dioxide (PaCO2). The alveolar gas equation demonstrates that an increase in PaCO2 causes a decrease in the alveolar partial pressure of oxygen (PAO2). In this situation, the A-a gradient is normal, as the PAO2 and PaO2 decrease in equal magnitudes. When severe, alveolar hypoventilation may progress to Type 2 respiratory failure.[8] (as discussed later in this section under Type 2 respiratory failure). 

• Low atmospheric pressure/fraction of inspired oxygen: The alveolar gas equation demonstrates that the alveolar partial pressure of oxygen (PAO2) decreases with low atmospheric pressures (Patm) and with low levels of inspired oxygen (FiO2). In either situation, the A-a gradient remains normal, and the PaCO2 is decreased, given the response to hypoxia is hyperventilation. Clinically, this cause of respiratory failure occurs at high altitudes.[9]

 Etiologies of Type 1 respiratory failure with increased A-a gradients include:

• Diffusion defect: Gas exchange between the environment and the body occurs at the alveolar-capillary interface. Structural changes to the alveolar component of the alveolar-capillary interface, such as decreased surface area or increased thickness, may result in diffusion defects across the membrane. Additionally, reducing pulmonary capillary transit time through the alveolar-capillary interface may result in diffusion defects across the membrane. In either situation, hypercapnia does not occur, as carbon dioxide diffuses more readily across the alveolar-capillary membrane than oxygen.[10] Etiologies of diffusion defects include:

  • Emphysema
  • Interstitial lung disease

• Ventilation/perfusion (V/Q) mismatch: The alveolar gas composition depends on the balance of alveolar ventilation and pulmonary capillary blood flow that occurs at the alveolar-capillary interface. When perfectly matched, the V/Q ratio is equal to one. When ventilation is excessive to perfusion, the V/Q ratio is greater than one; Dead space ventilation occurs when the V/Q ratio reaches infinity. When perfusion is excessive to ventilation, the V/Q ratio is less than one; Shunt occurs when the V/Q ratio reaches zero. In healthy subjects, however, the V/Q ratio is approximately 0.8, as the balance between ventilation and perfusion differs from the apex to the base of the lungs. V/Q mismatch is the most common cause of Type 1 respiratory failure.[11] Etiologies of V/Q mismatch include:

  • Acute respiratory distress syndrome
  • Chronic obstructive pulmonary disease
  • Congestive heart failure
  • Pulmonary embolism

• Right-to-left shunt: As discussed above, shunt occurs when the V/Q ratio reaches zero. The absence of gas exchange at the alveolar-capillary interface represents a true shunt and is analogous to intracardiac right-to-left shunting seen in atrial septal defect and patent foramen ovale. Unlike V/Q mismatch, true shunt does not improve with supplemental oxygen therapy.[12] Etiologies of pulmonary right-to-left shunts include:
  • Arteriovenous malformation
  • Complete atelectasis
  • Severe pneumonia
  • Severe pulmonary edema

Type 2 Respiratory Failure

Hypercapnic respiratory failure is defined as an increase in arterial carbon dioxide (CO2) (PaCO)> 45 mmHg with a pH < 7.35 due to respiratory pump failure and/or increased CO₂ production. In general, according to the modified alveolar ventilation equation, the PaCO2 level is proportionally related to the rate of CO2 production (VCO2) and inversely associated with the rate of CO2 elimination (i.e., alveolar ventilation) (PaCO2 =VCO2 /VA). The relationship between minute ventilation and CO2 production in response to exercise can be affected by age and pregnancy.[13] 

Alveolar ventilation (VA) is the product of minute ventilation (VE) and the ratio of dead space (VD) to tidal volume (Vt) (VA = VE x [1 - VD/Vt]). While decreased VA is the most common reason for the respiratory failure of hypercapnia, increased CO2 production is a very rare reason. Depending on the cause of respiratory failure, the partial pressure of oxygen (PaO2) may be normal or decreased. The two main paradigms responsible for hypercapnia respiratory failure are either manifested by "won't breathe" due to a central drive issue or "can't breathe" as a result of a peripheral neuromuscular defect, resistive loading (narrow airway) or restrictive defect that lead to hypoventilation and hypercapnia. 

Respiratory pump failure: The respiratory pump is comprised of the chest wall, the pulmonary parenchyma, the muscles of respiration, as well as the central and peripheral nervous systems. The inability to ventilate can occur if any of the components mentioned above of the respiratory pump fails.

• Decreased central dive: Sedatives (i.e., alcohol, benzodiazepines, and opiates) and diseases of the central nervous system (i.e., encephalitis, stroke, tumor, and SCI) may impair the respiratory drive, resulting in hypoventilation.[14]
• Altered neural and neuromuscular transmission: Amyotrophic lateral sclerosis, botulism, Guillain-Barre syndrome, myasthenia graves, organophosphate poisoning, poliomyelitis, spinal cord injury (SCI), tetanus, and transverse myelitis may impair the function of the respiratory pump, resulting in hypoventilation.[14]
• Chest wall and pleural disorders: Flail chest, kyphoscoliosis, hyperinflation, large pleural effusions, obesity, and thoracoplasty may impair the function of the respiratory pump, resulting in hypoventilation.
• Dead space ventilation: Conditions that increase the V/Q ratio, such as acute respiratory distress syndrome, bronchitis, bronchiectasis, emphysema, and pulmonary embolism, can result in hypoventilation. Hypoventilation typically occurs once dead space ventilation exceeds 50% of total ventilation.
• Muscle abnormalities: Diaphragmatic paralysis, diffuse atrophy, muscular dystrophy, and ruptured diaphragm may impair the function of the respiratory pump, resulting in hypoventilation. 

Increased dead space: Dead space (VD) refers to areas of the lung that are not anatomically or physiologically able to exchange gas. Tachypnea can contribute to high CO2 by increasing the dead space to tidal volume ratio (VD/Vt). High alveolar VA and the associated ventilation-perfusion mismatch are considered one of the main mechanisms for developing hypercapnia in individuals with COPD.[15]

Increased CO production: CO2 is a by-product of oxidative metabolism, and high CO2 production may occur due to fever, exercise, hyperalimentation, sepsis, and thyrotoxicosis. High CO₂ production becomes pathologic if the compensatory increase in minute ventilation mechanism fails.[16] 

Alveolar hypoventilation: Alveolar hypoventilation may progress to Type 2 respiratory failure.[8] (as discussed later in this section under Type 2 respiratory failure). 

History and Physical

Respiratory failure is a syndrome with a myriad of etiologies; therefore, a thorough history and physical examination are required to narrow the differential diagnosis.

History

Patients typically present with respiratory symptoms (i.e., dyspnea, cough, hemoptysis, sputum production, and wheezing); however, symptoms from other organ systems (ie, chest pain, decreased appetite, heartburn, fever, and significant weight loss) are important. Loss of smell and/or exposure to sick people or unprotect contact with individuals with coronavirus infection (COVID-19) is essential in suspecting COVID-19 illness and associated respiratory failure, particularly in high-risk patients (older patients, men, and morbidly obese).[17] For a specific population, the presence of immunocompromised conditions or taking immunosuppressants is also essential in risk-stratifying patients at risk for respiratory failure early on.

For patients already diagnosed with airway disease, it is important to assess inhaler compliance and technique, recent steroid use, as well as exposure to environmental triggers. For patients with hypertension and chronic cough, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers should be investigated.

Social history is also crucial when considering respiratory failure. Alcohol use and sexually transmitted diseases may lead to an immunocompromised state, making patients more susceptible to certain infections, while a sedentary lifestyle may increase the risk of pulmonary embolism. Habits such as having birds and hobbies such as diving and flying may have implications when considering etiologies of respiratory failure. Most importantly, a patient's tobacco smoking history should be investigated, including exposure to second-hand smoke, marijuana smoking, smoking e-cigarettes, and vaping.[18]

Finally, an occupational history may be helpful when considering work-related lung disease (i.e., hypersensitivity pneumonitis and pneumoconiosis), while a family history may be beneficial when considering atopic, genetic (ie, alpha-1-antitrypsin deficiency and cystic fibrosis), and infectious diseases (i.e., tuberculosis).[19]

Physical Examination

Signs of respiratory failure may be present throughout the body. Physical examination findings by region appear below:

• General inspection: Accessory muscle use, altered mental status, cachectic, conversational dyspnea, diaphoresis, fever, respiratory distress (i.e., at rest or with exertion), obesity, and purse-lipped breathing
• Head: Cushingoid appearance, central cyanosis, Horner's syndrome, and pale conjunctiva
• Neck: Jugular venous distention, lymphadenopathy, and tracheal deviation
• Chest/thorax: Asymmetrical chest expansion, bradypnea, bronchial breath sounds, Cheyne-Stoke breathing, crackles, decreased breath sounds, dullness to percussion, hyper-resonance to percussion, Kussmaul breathing, kyphoscoliosis, loud P2, paradoxical breathing, pectus carinatum, pectus excavatum, pleural rub, reduced chest expansion, rhonchi, stridor, tachypnea, tactile vocal fremitus, vesicular breath sounds, vocal resonance, wheezes, and whispering pectoriloquy
• Abdomen: Hepatomegaly
• Upper extremities: Asterixis, digital clubbing, peripheral cyanosis, tobacco staining, and tremor
• Lower extremities: Edema, peripheral cyanosis, and unilateral swelling.[20]

Evaluation

As discussed above, respiratory failure is a syndrome caused by a multitude of pathological states. As such, a single algorithm for evaluating respiratory failure does not exist. Appropriate diagnostic studies may include laboratory assays (i.e., complete blood count with the differential, comprehensive metabolic panel with magnesium/phosphorous, procalcitonin, troponin, and thyroid-stimulating hormone), infectious workup (i.e., blood cultures, sputum cultures, respiratory pathogen panel test, and urinary antigen test), and 12-lead electrocardiography. Evaluation of respiratory failure with arterial blood gas, capnometry, radiography, pulse oximetry, and ultrasonography are discussed below.

Arterial Blood Gas

Arterial blood gas (ABG) is the gold standard for diagnosing respiratory failure. At a minimum, the information obtained from an ABG includes pH, partial pressure of arterial oxygen (PaO2), partial pressure of arterial carbon dioxide (PaCO2), and serum bicarbonate (HCO3). It should be noted that the HCO3 obtained from an ABG is a calculated value and may, therefore, be inaccurate. Analysis of an ABG should instead be performed using a measured HCO3 obtained from a basic metabolic panel.

Oxygenation is assessed through the interpretation of the PaO2. Hypoxemia is defined as a PaO2 less than 60 mmHg. Ventilation is assessed through the interpretation of the PaCO2. Hypercapnia is defined as a PaCO2 greater than 45 mmHg.

Information from the ABG can also be used to differentiate acute from chronic respiratory failure by evaluating the renal response to PaCO2. In respiratory acidosis, the kidneys respond by increasing the absorption of HCO3 in the proximal convoluted tube. As this is a slow process, the magnitude of HCO3 absorption in acute respiratory acidosis is less than the magnitude of HCO3 absorption in chronic respiratory acidosis. This difference allows for the distinction between the chronicity in acute and chronic respiratory failure.[21]

Capnometry

Capnometry, the measurement of carbon dioxide in exhaled gas, may be qualitative or quantitative. Colorimetric capnometry is a qualitative measure of carbon dioxide in exhaled gas that relies on the color change of a pH-sensitive indicator. Infrared capnometry is a quantitative measure of carbon dioxide in exhaled gas that relies on measuring the partial pressure of carbon dioxide (pCO2). Quantitative capnometry provides more information than qualitative capnometry.[22]

In the non-pathological state, the partial pressure of carbon dioxide at the end of expiration, or end-tidal pCO2 (PETCO2), approximates the partial pressure of carbon dioxide in the arterial blood (PaCO2). The PaCO2 is typically 2 to 3 mmHg greater than the PETCO2. In the pathological state, where gas exchange is impaired, the difference between the PaCO2 and PETCO2 becomes greater than 3 mmHg due to increased dead space ventilation.[23]

Values obtained from quantitative capnometry can be plotted graphically and displayed as waveform capnography. Analysis of these waveforms allows for detecting pathological states (i.e., apnea, bronchospasm, hyperventilation, and hypoventilation).[24] 

Radiography

Various imaging modalities are available for the evaluation of respiratory failure. Such options include plain films, computed tomography, magnetic resonance, nuclear medicine, angiography, and ultrasonography.[25] 

Pulse Oximetry

Pulse oximetry relies on spectrophotometry, the process of identifying the composition of a substance via measurement of the absorption of specific wavelengths of light transmitted through the substance in question. The composition and structural configuration of hemoglobin are dependent upon molecular oxygen. In the tense state, oxygenated hemoglobin has a lower affinity for oxygen. In the relaxed state, deoxygenated hemoglobin has a higher affinity for oxygen. Pulse oximetry takes advantage of the conformational states of the hemoglobin molecule as deoxygenated hemoglobin absorbs light at wavelengths of 660 nm, and oxygenated hemoglobin absorbs light at wavelengths of 940 nm. Measurement of arterial oxygenation is ensured through the analysis of pulsatile blood. Proprietary algorithms allow for the conversion of light absorption to the fraction of hemoglobin saturated with oxygen, known as oxygen saturation (SpO2). This non-invasive modality is greatly useful in diagnosing and managing respiratory failure.[26]

Ultrasonography

The bedside lung ultrasound in emergency (BLUE)-protocol is the bedside gold standard for the immediate diagnosis of acute respiratory failure. The protocol allows for reproducible analysis and relies on standardized thoracic locations (BLUE points) and ten ultrasonographic signs or profiles. The BLUE protocol is performed by analyzing the ultrasonographic profiles obtained at each of the three BLUE points on each side of the body. The standardized BLUE points are known as the Upper BLUE point, the Lower BLUE point, and the postero-lateral alveolar and/or pleural syndrome (PLAPS)-point. In total, there are six BLUE points. The theory behind and the application of the BLUE protocol are beyond the scope of this article; however, the ten ultrasonographic profiles are grouped with their corresponding clinical states below:

• Normal lung surface: Bat sign, lung sliding, and A-lines
• Interstitial syndrome: Lung rockets
• Lung consolidations: Fractal and tissue-like signs
• Pleural effusions: Quad and sinusoid sign
• Pneumothorax: Stratosphere sign and the lung point. [27]

Bronchoscopy, echocardiography, nocturnal polysomnography, and pulmonary function tests may also be included in evaluating respiratory failure. Pulmonary consultation is warranted if the aforementioned diagnostic studies are required.

Treatment / Management

Treatment of respiratory failure should be directed towards the underlying cause while providing support with oxygenation and ventilation, if necessary. The treatment includes supportive measures and treatment of the underlying cause. However, the initial steps in managing patients with acute respiratory failure should start by assessing the airway, breathing, and circulation (ABC). Supportive measures depend on patent airways to maintain adequate oxygenation, ventilation, and correction of blood gas abnormalities.

Correction of Hypoxemia

The goal is to maintain adequate tissue oxygenation, generally achieved with an arterial oxygen tension (PaO2) of 60 mm Hg or arterial oxygen saturation (SaO2), about 90%.

Uncontrolled oxygen supplementation can result in oxygen toxicity and CO2 (carbon dioxide) narcosis. The inspired oxygen concentration should be adjusted at the lowest level (90-94%), which is sufficient for tissue oxygenation.

Oxygen can be delivered by several routes depending on the clinical situations in which we may use a nasal cannula, simple face mask, nonrebreathing mask, or high-flow nasal cannula.

Extracorporeal membrane oxygenation may be needed in refractory cases.[28]

Correction of Hypercapnia and Respiratory Acidosis 

This may be achieved by treating the underlying cause or providing ventilatory support.[29]

Ventilatory Support

Patients with severe acute respiratory failure are usually intubated. The goals of ventilatory support in respiratory failure are to:

• Correct hypoxemia
• Correct acute respiratory acidosis
• Resting of ventilatory muscles

Common Indications for Mechanical Ventilation Include the Following

• Apnea with respiratory arrest
• Tachypnea with respiratory rate >30 breaths per minute
• Disturbed conscious level or coma
• Respiratory muscle fatigue
• Hemodynamic instability
• Failure of supplemental oxygen to increase PaO2 to 55 to 60 mmHg
• Hypercapnia with arterial pH less than 7.25[30]

The choice of invasive or noninvasive ventilatory support depends on the clinical situation, whether the condition is acute or chronic, and how severe it is.[31] It also depends on the underlying cause. Noninvasive ventilation (NIV) is preferred, particularly in cases of chronic obstructive pulmonary disease (COPD) exacerbation, cardiogenic pulmonary edema, and obesity hypoventilation syndrome.[32][33][34][33][35][36]

Differential Diagnosis

The differential diagnosis for respiratory failure is broad and includes, but is not limited to, the following:

• Acute respiratory distress syndrome
• Aspiration pneumonia
• Aspiration pneumonitis
• Asthma
• Atelectasis
• Bacterial pneumonia
• Bronchitis
• Cardiogenic pulmonary edema
• Cardiogenic shock
• Central sleep apnea
• Cervical cord injury
• Cor pulmonale
• Diaphragmatic paralysis
• Distributive shock
• Drug overdose
• Emphysema
• Fat embolism
• Granulomatous lung disease
• Idiopathic pulmonary arterial hypertension
• Kyphoscoliosis
• Myxedema
• Myocardial infarction
• Neurogenic pulmonary edema
• Obesity hypoventilation syndrome
• Obstructive shock
• Obstructive sleep apnea
• Pleural effusion
• Pneumothorax
• Pulmonary fibrosis
• Restrictive lung disease
• Pneumoconiosis
• Primary muscle disorders
• Pulmonary arterial hypertension
• Pulmonary embolism
• Viral pneumonia

Prognosis

 Respiratory failure is a syndrome caused by a multitude of pathological states; therefore, the prognosis of this disease process is difficult to ascertain. In 2017, in the United States of America, however, the in-hospital respiratory failure mortality rate was 12%. The case definition used in this study included all diagnosis codes, which included respiratory failure.[2] In-hospital mortality rates for patients requiring intubation with mechanical ventilation for asthma exacerbation, acute exacerbation of chronic obstructive pulmonary disease, and pneumonia were found to be 9.8%, 38.3%, and 48.4%, respectively.[37][38][39] Lastly, the in-hospital mortality rate for acute respiratory distress syndrome was found to be 44.3%.[40]

Complications

Respiratory failure is associated with both pulmonary and extrapulmonary complications, especially in the acute setting. Pulmonary complications include bronchopleural fistula, nosocomial pneumonia, pneumothorax, pulmonary embolism, and pulmonary fibrosis, while extrapulmonary complications include acid-base disturbances, decreased cardiac output, gastrointestinal hemorrhage, hepatic failure, ileus, infection, increased intracranial pressure, malnutrition, pneumoperitoneum, renal failure, and thrombocytopenia. Clinicians should be aware of the conditions mentioned earlier and be prepared to offer prophylactic therapy or proper treatment for such complications when applicable.[41][42]

Consultations

Depending on the severity of the respiratory failure, consultation with a Pulmonary specialist may be warranted in the patient's care.

Deterrence and Patient Education

While patients should be educated on the symptoms of respiratory failure, they should also be aware of the importance of device and medication compliance, as well as modifiable risk factors and how they relate to disease prevention. For instance, the following strategies are efficacious in preventing acute exacerbations of chronic obstructive pulmonary disease: Adherence to pharmacological therapy, pulmonary rehabilitation, smoking cessation, and vaccination (i.e., influenza and pneumococcal).[43] Unfortunately, not all causes of respiratory failure are preventable. Patients should seek prompt evaluation and treatment if they become symptomatic.

Enhancing Healthcare Team Outcomes

Diagnosing the underlying cause of respiratory failure and its treatment is challenging as this syndrome can result from numerous pulmonary and extrapulmonary causes. Therefore, consultation with other specialties (i.e., cardiology and neurology) may be mandatory. Moreover, discussing radiographic findings with a radiologist can sometimes be necessary. Additionally, complications from respiratory failure may be due to improper patient positioning and poor adherence to infection control policies. Fortunately, nurses are vital interprofessional healthcare team members, assuring appropriate patient positioning. Nursing is also responsible for feeding, monitoring, and suctioning the patient and can offer patient counseling while serving as a contact point for the various specialties involved in the case. All interprofessional team members are responsible for keeping meticulous records of every interaction and intervention with the patient so that every care team member has access to the same accurate, updated patient information.

Since patients with respiratory failure may require multiple medications, the pharmacist is instrumental in ensuring safe medication administration, medication reconciliation, answering drug questions for the care team, and providing medication counseling for the patient. Finally, respiratory therapists also care for a patient with respiratory failure (i.e., administration of oxygen and chest physiotherapy). All interprofessional team members must engage in meticulous documentation and report any changes in patient status to the appropriate team members for possible corrective action. This interprofessional team works to improve patient care and outcomes through collaborative activity and open communication. [Level 5]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Haddad M, Sharma S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 20, 2023. Physiology, Lung. [PubMed: 31424761]

2.

Kempker JA, Abril MK, Chen Y, Kramer MR, Waller LA, Martin GS. The Epidemiology of Respiratory Failure in the United States 2002-2017: A Serial Cross-Sectional Study. Crit Care Explor. 2020 Jun;2(6):e0128. [PMC free article: PMC7314331] [PubMed: 32695994]

3.

Vallabhajosyula S, Kashani K, Dunlay SM, Vallabhajosyula S, Vallabhajosyula S, Sundaragiri PR, Gersh BJ, Jaffe AS, Barsness GW. Acute respiratory failure and mechanical ventilation in cardiogenic shock complicating acute myocardial infarction in the USA, 2000-2014. Ann Intensive Care. 2019 Aug 28;9(1):96. [PMC free article: PMC6713772] [PubMed: 31463598]

4.

Hendrickson KW, Peltan ID, Brown SM. The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019. Crit Care Clin. 2021 Oct;37(4):703-716. [PMC free article: PMC8449138] [PubMed: 34548129]

5.

Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR, Salazar-Schicchi J, Yip NH, Brodie D, O'Donnell MR. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020 Jun 06;395(10239):1763-1770. [PMC free article: PMC7237188] [PubMed: 32442528]

6.

Ozsancak Ugurlu A, Habesoglu MA. Epidemiology of NIV for Acute Respiratory Failure in COPD Patients: Results from the International Surveys vs. the "Real World". COPD. 2017 Aug;14(4):429-438. [PubMed: 28636452]

7.

Conkin J. Equivalent Air Altitude and the Alveolar Gas Equation. Aerosp Med Hum Perform. 2016 Jan;87(1):61-4. [PubMed: 26735235]

8.

Hantzidiamantis PJ, Amaro E. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 5, 2023. Physiology, Alveolar to Arterial Oxygen Gradient. [PubMed: 31424737]

9.

Sharma S, Hashmi MF, Burns B. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 22, 2022. Alveolar Gas Equation. [PubMed: 29489223]

10.

Bhutta BS, Alghoula F, Berim I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 4, 2024. Hypoxia. [PubMed: 29493941]

11.

Powers KA, Dhamoon AS. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 23, 2023. Physiology, Pulmonary Ventilation and Perfusion. [PubMed: 30969729]

12.

Shahjehan RD, Abraham J. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 2, 2023. Intracardiac Shunts. [PubMed: 32644395]

13.

Schaeffer MR, Guenette JA, Jensen D. Impact of ageing and pregnancy on the minute ventilation/carbon dioxide production response to exercise. Eur Respir Rev. 2021 Sep 30;30(161) [PMC free article: PMC9488679] [PubMed: 34289982]

14.

Bascom AT, Sankari A, Goshgarian HG, Badr MS. Sleep onset hypoventilation in chronic spinal cord injury. Physiol Rep. 2015 Aug;3(8) [PMC free article: PMC4562576] [PubMed: 26290534]

15.

Chuang ML, Hsieh BY, Lin IF. Prediction and types of dead-space fraction during exercise in male chronic obstructive pulmonary disease patients. Medicine (Baltimore). 2022 Feb 11;101(6):e28800. [PMC free article: PMC8830857] [PubMed: 35147114]

16.

Rawat D, Modi P, Sharma S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 24, 2023. Hypercapnea. [PubMed: 29763188]

17.

Raschke RA, Rangan P, Agarwal S, Uppalapu S, Sher N, Curry SC, Heise CW. COVID-19 Time of Intubation Mortality Evaluation (C-TIME): A system for predicting mortality of patients with COVID-19 pneumonia at the time they require mechanical ventilation. PLoS One. 2022;17(7):e0270193. [PMC free article: PMC9258832] [PubMed: 35793312]

18.

Eddy RL, Serajeddini H, Knipping D, Landman ST, Bosma KJ, Mackenzie CA, Dhaliwal I, Parraga G. Pulmonary Functional MRI and CT in a Survivor of Bronchiolitis and Respiratory Failure Caused by e-Cigarette Use. Chest. 2020 Oct;158(4):e147-e151. [PubMed: 32544490]

19.

STUART-HARRIS CH. SHORTNESS OF BREATH. Br Med J. 1964 May 09;1(5392):1203-9. [PMC free article: PMC1814385] [PubMed: 14120825]

20.

Simpson H. Respiratory assessment. Br J Nurs. 2006 May 11-24;15(9):484-8. [PubMed: 16723920]

21.

Castro D, Patil SM, Zubair M, Keenaghan M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 8, 2024. Arterial Blood Gas. [PMC free article: PMC536919] [PubMed: 30725604]

22.

Nowicki T, Jamal Z, London S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 29, 2023. Carbon Dioxide Detector. [PubMed: 29489155]

23.

Siobal MS. Monitoring Exhaled Carbon Dioxide. Respir Care. 2016 Oct;61(10):1397-416. [PubMed: 27601718]

24.

Thompson JE, Jaffe MB. Capnographic waveforms in the mechanically ventilated patient. Respir Care. 2005 Jan;50(1):100-8; discussion 108-9. [PubMed: 15636648]

25.

Gulati A, Balasubramanya R. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Lung Imaging. [PubMed: 32644402]

26.

Torp KD, Modi P, Pollard EJ, Simon LV. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Pulse Oximetry. [PubMed: 29262014]

27.

Lichtenstein DA. BLUE-protocol and FALLS-protocol: two applications of lung ultrasound in the critically ill. Chest. 2015 Jun;147(6):1659-1670. [PubMed: 26033127]

28.

Moerer O, Vasques F, Duscio E, Cipulli F, Romitti F, Gattinoni L, Quintel M. Extracorporeal Gas Exchange. Crit Care Clin. 2018 Jul;34(3):413-422. [PubMed: 29907273]

29.

Faverio P, De Giacomi F, Sardella L, Fiorentino G, Carone M, Salerno F, Ora J, Rogliani P, Pellegrino G, Sferrazza Papa GF, Bini F, Bodini BD, Messinesi G, Pesci A, Esquinas A. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulm Med. 2018 May 15;18(1):70. [PMC free article: PMC5952859] [PubMed: 29764401]

30.

Cavalleri M, Barbagelata E, Diaz de Teran T, Ferraioli G, Esquinas A, Nicolini A. Noninvasive and invasive ventilation in severe pneumonia: Insights for the noninvasive ventilatory approach. J Crit Care. 2018 Dec;48:479. [PubMed: 30126747]

31.

Gong Y, Sankari A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 11, 2022. Noninvasive Ventilation. [PubMed: 35201716]

32.

Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, Navalesi P, Antonelli M, Brozek J, Conti G, Ferrer M, Guntupalli K, Jaber S, Keenan S, Mancebo J, Mehta S, Raoof S. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017 Aug;50(2) [PubMed: 28860265]

33.

Fazekas AS, Aboulghaith M, Kriz RC, Urban M, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Funk GC. Long-term outcomes after acute hypercapnic COPD exacerbation : First-ever episode of non-invasive ventilation. Wien Klin Wochenschr. 2018 Oct;130(19-20):561-568. [PMC free article: PMC6209011] [PubMed: 30066095]

34.

Miró Ò, Martínez G, Masip J, Gil V, Martín-Sánchez FJ, Llorens P, Herrero-Puente P, Sánchez C, Richard F, Lucas-Invernón J, Garrido JM, Mebazaa A, Ríos J, Peacock WF, Hollander JE, Jacob J., ICA-SEMES Research Group Researchers. Effects on short term outcome of non-invasive ventilation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry. Eur J Intern Med. 2018 Jul;53:45-51. [PubMed: 29572091]

35.

Fernández Álvarez R, Rubinos Cuadrado G, Ruiz Alvarez I, Hermida Valverde T, Iscar Urrutia M, Vázquez Lopez MJ, Casan Clara P. Hypercapnia Response in Patients with Obesity-Hypoventilation Syndrome Treated with Non-Invasive Ventilation at Home. Arch Bronconeumol (Engl Ed). 2018 Sep;54(9):455-459. [PubMed: 29871766]

36.

Antoine MH, Sankari A, Bollu PC. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 11, 2024. Obesity-Hypoventilation Syndrome. [PubMed: 29493925]

37.

Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care. 2006;10 Suppl 2(Suppl 2):S1. [PMC free article: PMC3226135] [PubMed: 16934135]

38.

Gupta D, Keogh B, Chung KF, Ayres JG, Harrison DA, Goldfrad C, Brady AR, Rowan K. Characteristics and outcome for admissions to adult, general critical care units with acute severe asthma: a secondary analysis of the ICNARC Case Mix Programme Database. Crit Care. 2004 Apr;8(2):R112-21. [PMC free article: PMC420044] [PubMed: 15025785]

39.

Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003 May 26;163(10):1180-6. [PubMed: 12767954]

40.

Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, Scales DC, Stather DR, Li A, Jones A, Gattas DJ, Hallett D, Tomlinson G, Stewart TE, Ferguson ND. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am J Respir Crit Care Med. 2009 Feb 01;179(3):220-7. [PubMed: 19011152]

41.

Pingleton SK. Complications of acute respiratory failure. Med Clin North Am. 1983 May;67(3):725-46. [PubMed: 6405105]

42.

Pierson DJ. Complications associated with mechanical ventilation. Crit Care Clin. 1990 Jul;6(3):711-24. [PubMed: 2199002]

43.

Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J., Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. [PubMed: 17507545]

Disclosure: Vincent Mirabile declares no relevant financial relationships with ineligible companies.

Disclosure: Eman Shebl declares no relevant financial relationships with ineligible companies.

Disclosure: Abdulghani Sankari declares no relevant financial relationships with ineligible companies.

Disclosure: Bracken Burns declares no relevant financial relationships with ineligible companies.